NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition
Authors:
- Alexander JaisAJAlexander Jais
Open Access
- 7 November 2022
- journal article
- research article
- Published by Elsevier in Molecular Metabolism
- Vol. 66, 101626
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer developmentMolecular and Cellular Endocrinology, 2012
- NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathwayOncogene, 2011
- Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in miceHepatology, 2011
- Non-canonical NF-κB signaling pathwayCell Research, 2010
- A single NFκB system for both canonical and non-canonical signalingCell Research, 2010
- The Transcription Factors Signal Transducer and Activator of Transcription 5A (STAT5A) and STAT5B Negatively Regulate Cell Proliferation Through the Activation of Cyclin-Dependent Kinase Inhibitor 2b ( Cdkn2b ) and Cdkn1a ExpressionHepatology, 2010
- NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cellsProceedings of the National Academy of Sciences, 2008
- Experimental models of hepatocellular carcinomaJournal of Hepatology, 2008
- Hepatic NF-κB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesisProceedings of the National Academy of Sciences, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007